Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) disclosed two forthcoming share-reduction initiatives involving a combined ceiling of 21.42 million A-shares between 20 May 2026 and 19 Aug 2026.

Shanghai Tanying Investment Partnership (LP) currently owns 59.46 million A-shares, equal to 5.79 % of Junshi Bio’s issued capital. To meet fund-maturity and liquidity requirements, the private-equity vehicle intends to dispose of no more than 20.53 million shares—capped at 2 % of outstanding equity—through block trades. The transaction window opens on the 15th trading day after this disclosure and remains valid for three months. Execution timing, price and volume remain subject to market conditions.

Separately, Ms. He Ming—former spouse of Executive Director and Co-CEO Mr. Li Cong—holds 3.53 million A-shares (0.34 %). For personal funding needs, she plans to divest up to 0.88 million shares (0.09 % of total equity) via centralized bidding within the same three-month period. The intended sale volume represents less than 25 % of her pre-IPO holdings, satisfying STAR Market lock-up regulations.

Both parties reaffirm compliance with their original lock-up and pricing undertakings, notably a floor price not lower than the IPO issue price for sales within two years of lock-up expiry. The company confirmed that neither transaction will trigger a change in control and that both shareholders are clear of any regulatory restrictions that would prohibit the planned disposals.

Junshi Bio cautions that each shareholder may elect to execute, partially execute or abandon the planned reductions depending on prevailing market conditions, leaving timing, pricing and final quantities uncertain. The firm pledges timely disclosure of progress and urges investors to monitor subsequent announcements for updates.